Immunosuppressive drugs and fetal outcome

    Authors

    L. A. Coscia; S. Constantinescu; J. M. Davison; M. J. Moritz;V. T. Armenti

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Best Pract. Res. Clin. Obstet. Gynaecol.

    Keywords

    transplantation; pregnancy; immunosuppression; fetus; ORGAN TRANSPLANT RECIPIENTS; MYCOPHENOLIC-ACID PRODUCTS; RENAL-ALLOGRAFT; RECIPIENTS; PREGNANCY OUTCOMES; CYCLOSPORINE; KIDNEY; EXPOSURE; AZATHIOPRINE; EVEROLIMUS; SIROLIMUS; Obstetrics & Gynecology

    Abstract

    Successful pregnancies have been reported in all types of solidorgan transplant recipients on a variety of immunosuppressive regimens. Immunosuppression is essential to maintain the transplanted organ and maternal health, thus the safety of these medications continues to be studied. This article reviews information in the literature and data from the National Trans-, plantation Pregnancy Registry (NTPR) in the United States related to immunosuppressive medication and pregnancy. Although most maintenance immunosuppressive regimens have not been shown to affect the outcome of posttransplant pregnancies, mycophenolic acid products are associated with an increased incidence of spontaneous abortion and an increase in the incidence and a specific pattern of birth defects. When counseling transplant recipients about the prospect and safety of pregnancy, the health of the mother, her graft, and the developing fetus must all be taken into account. (C) 2014 Elsevier Ltd. All rights reserved.

    Journal Title

    Best Practice & Research Clinical Obstetrics & Gynaecology

    Volume

    28

    Issue/Number

    8

    Publication Date

    1-1-2014

    Document Type

    Article

    Language

    English

    First Page

    1174

    Last Page

    1187

    WOS Identifier

    WOS:000346212700007

    ISSN

    1521-6934

    Share

    COinS